Stoke Therapeutics (STOK) Interest Expenses (2020 - 2026)
Stoke Therapeutics (STOK) posted quarterly Interest Expenses of $23000.0 for Q1 2026, up 2200.0% year-over-year from $1000.0 in Q1 2025, and down 97.9% quarter-over-quarter from $1.1 million in Q4 2025.
Stoke Therapeutics (STOK) Interest Expenses (2020 - 2026) Analysis & Trends
Stoke Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $23000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 2200.0% year-over-year to $23000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 43.9% YoY), while the FY2025 annual figure was $184.4 million, up 802.85% from the prior year.
- Interest Expenses for Q1 2026 stood at $23000.0, down from $1.1 million in the prior quarter.
- The five-year high for Interest Expenses was $133.3 million in Q4 2023, with the low at $1000.0 in Q1 2025.
- The 5-year median for Interest Expenses is $728500.0 (2022), against an average of $15.8 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 99.88% in 2024, then surged 116440.0% in 2025.
- Stoke Therapeutics' Interest Expenses stood at $97.9 million in 2022, then soared by 36.17% to $133.3 million in 2023, then tumbled by 99.42% to $773000.0 in 2024, then surged by 41.53% to $1.1 million in 2025, then plunged by 97.9% to $23000.0 in 2026.
- Business Quant data shows STOK's Interest Expenses at $23000.0 in Q1 2026, $1.1 million in Q4 2025, and $3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 2.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.86 Mn |
| Jun 30, 2026 | 2.86 Mn |
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 5.83 Mn |
| Jun 30, 2025 | 5.83 Mn |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 773,000.00 |
| Dec 31, 2024 | 773,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Dec 31, 2023 | 133.31 Mn |
| Dec 31, 2023 | 133.31 Mn |